Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Abstract

Trusted evidence. Informed decisions. Better health.

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

“…Our findings are consistent with previous evidence indicating that HPV vaccination is not associated with a lower risk of cervical cancer among women vaccinated after the age of 20 24,25 . A large Cochrane review found no reduction in CIN2+ risk among women vaccinated above the age of 25 years compared to unvaccinated, regardless of HPV DNA status 26,27 . A recent study found that women undergoing active surveillance for CIN2 had a 35% lower risk of progression if they had received the HPV vaccine before age 15 compared to unvaccinated women, while no difference was observed in risk of progression for women vaccinated after age 20 20 .…”

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

“…Our findings are consistent with previous evidence indicating that HPV vaccination is not associated with a lower risk of cervical cancer among women vaccinated after the age of 20 24,25 . A large Cochrane review found no reduction in CIN2+ risk among women vaccinated above the age of 25 years compared to unvaccinated, regardless of HPV DNA status 26,27 . A recent study found that women undergoing active surveillance for CIN2 had a 35% lower risk of progression if they had received the HPV vaccine before age 15 compared to unvaccinated women, while no difference was observed in risk of progression for women vaccinated after age 20 20 .…”

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

“…Furthermore, a recent publication [24] suggested that cross-protection is higher in 2-valent vaccine recipients compared to 4-valent vaccine recipients. These findings are in line with the recent Cochrane review [25] which also showed similar protection of 2-valent and 4-valent vaccines against cervical pre-cancers related to types 16/18, but concluded that the 2-valent vaccine offered better protection against cervical pre-cancers overall. From an immunogenicity perspective, several studies have so far reported significantly higher antibody levels against vaccine and non-vaccine types elicited by the 2-valent vaccine compared to 4-valent one [26][27][28].…”

Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya—Findings and Implications

“…Of concern is that approximately 10% of parents were hesitant to have their children vaccinated, with safety concerns (76%) a notable reason. This is similar other studies in Kenya revealing safety concerns [ 11 , 17 , 29 , 30 ] alongside inadequate information [ 20 ]. Lack of knowledge regarding the HPV vaccine among health care workers, alongside misinformation that the vaccine is a form of contraception and encourages pre-marital sex, are concerns that need to be addressed going forward [ 29 , 30 , 64 , 65 ].…”

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

“…Our findings are consistent with previous evidence indicating that HPV vaccination is not associated with a lower risk of cervical cancer among women vaccinated after the age of 20 24,25 . A large Cochrane review found no reduction in CIN2+ risk among women vaccinated above the age of 25 years compared to unvaccinated, regardless of HPV DNA status 26,27 . A recent study found that women undergoing active surveillance for CIN2 had a 35% lower risk of progression if they had received the HPV vaccine before age 15 compared to unvaccinated women, while no difference was observed in risk of progression for women vaccinated after age 20 20 .…”

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

“…Furthermore, a recent publication [24] suggested that cross-protection is higher in 2-valent vaccine recipients compared to 4-valent vaccine recipients. These findings are in line with the recent Cochrane review [25] which also showed similar protection of 2-valent and 4-valent vaccines against cervical pre-cancers related to types 16/18, but concluded that the 2-valent vaccine offered better protection against cervical pre-cancers overall. From an immunogenicity perspective, several studies have so far reported significantly higher antibody levels against vaccine and non-vaccine types elicited by the 2-valent vaccine compared to 4-valent one [26][27][28].…”

Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya—Findings and Implications

“…Of concern is that approximately 10% of parents were hesitant to have their children vaccinated, with safety concerns (76%) a notable reason. This is similar other studies in Kenya revealing safety concerns [ 11 , 17 , 29 , 30 ] alongside inadequate information [ 20 ]. Lack of knowledge regarding the HPV vaccine among health care workers, alongside misinformation that the vaccine is a form of contraception and encourages pre-marital sex, are concerns that need to be addressed going forward [ 29 , 30 , 64 , 65 ].…”

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

“…Our findings are consistent with previous evidence indicating that HPV vaccination is not associated with a lower risk of cervical cancer among women vaccinated after the age of 20 24,25 . A large Cochrane review found no reduction in CIN2+ risk among women vaccinated above the age of 25 years compared to unvaccinated, regardless of HPV DNA status 26,27 . A recent study found that women undergoing active surveillance for CIN2 had a 35% lower risk of progression if they had received the HPV vaccine before age 15 compared to unvaccinated women, while no difference was observed in risk of progression for women vaccinated after age 20 20 .…”

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

“…Furthermore, a recent publication [24] suggested that cross-protection is higher in 2-valent vaccine recipients compared to 4-valent vaccine recipients. These findings are in line with the recent Cochrane review [25] which also showed similar protection of 2-valent and 4-valent vaccines against cervical pre-cancers related to types 16/18, but concluded that the 2-valent vaccine offered better protection against cervical pre-cancers overall. From an immunogenicity perspective, several studies have so far reported significantly higher antibody levels against vaccine and non-vaccine types elicited by the 2-valent vaccine compared to 4-valent one [26][27][28].…”

Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya—Findings and Implications

“…Of concern is that approximately 10% of parents were hesitant to have their children vaccinated, with safety concerns (76%) a notable reason. This is similar other studies in Kenya revealing safety concerns [ 11 , 17 , 29 , 30 ] alongside inadequate information [ 20 ]. Lack of knowledge regarding the HPV vaccine among health care workers, alongside misinformation that the vaccine is a form of contraception and encourages pre-marital sex, are concerns that need to be addressed going forward [ 29 , 30 , 64 , 65 ].…”